plerixafor has been researched along with Body Weight in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ilyushina, M; Khismatullina, R; Kurnikova, E; Maschan, A; Maschan, M; Novichkova, G; Pershin, D; Trakhtman, P | 1 |
| Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N | 1 |
| Dohrmann, T; Drenckhan, A; Effenberger, K; Forberich, E; Gros, SJ; Hoffman, RM; Izbicki, JR; Kaifi, JT; Kurschat, N; Pantel, K; Reichelt, U | 1 |
3 other study(ies) available for plerixafor and Body Weight
| Article | Year |
|---|---|
Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Infant; Male; Pediatrics; Receptors, Antigen, T-Cell, alpha-beta; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2021 |
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Benzylamines; Body Weight; Bone Marrow; Cell Line, Tumor; Cell Movement; Cyclams; Disease Models, Animal; Esophageal Neoplasms; Female; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, CXCR4; Reproducibility of Results; Trastuzumab; Tumor Burden; Up-Regulation | 2012 |